Anthrax treatment for patients with inhalational anthrax
Part of Infections clinical trials.
This study tests a treatment called AIGIV (sometimes sold as Anthrasil) for people who get anthrax by breathing in the germs. The treatment is made from human antibodies that fight the anthrax toxin, and the study checks if it is safe and helps patients recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have or are likely to have anthrax in your lungs (inhalational anthrax), linked to a known exposure event.
- You are willing to receive the study treatment, AIGIV, given through an IV line.
- You (or your guardian) can agree to participate by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients who have been diagnosed with or are suspected to have systemic anthrax and are being treated with the medicine AIGIV. It aims to understand how well the treatment works and whether it is safe. The results may help improve care for people with this serious infection.
This study is for people who have symptoms of inhalational anthrax after a mass exposure. It tests a medicine called raxibacumab to see if it helps and is safe. Anyone who receives this medicine as part of their care can join.
This study observes people in the US who have been diagnosed with systemic anthrax and treated with a medication called raxibacumab, which was given from a national emergency supply. The goal is to learn more about how this treatment works in real-world cases.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This trial tests whether delivering medication through a ventilator mask (aerosol therapy) can help adults with ARDS breathe better. It is designed for patients who are already on a breathing machine.
This trial tests whether an inhaled antibiotic (amikacin) can help clear a lung infection called ventilator-associated tracheobronchitis in patients who are on a breathing machine. It may reduce infection and improve recovery.
Hear when a new Inhalational Anthrax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.